Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institut Curie
Age
18–75
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Breast adenocarcinoma considered HER2-negative on the primary tumour or unknown status HER2
A least one metastatic site and/or inoperable loco-regional relapse
Measurable disease (RECIST v1.1)
Age from 18 to 75 years
Performance status of 0-2
Efficient contraceptive in non-menopause women
At least 1 (Cohort " L ") or 3 (cohort " H ") HER2 amplified CTC
Performance status of 0-2
Adequate cardiac function
Adequate hematological and biochemical blood tests
You may not be if
Life expectancy of less than 3 months
Previous history of any other stage III or IV invasive cancer
Male breast cancer
Uncontrolled brain metastases
Significant cumulated exposure to anthracyclines
Current or previous significant history of cardio-vascular/pulmonary disease
Previous use of trastuzumab
Clareo Health | Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
